Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coordination abnormal17.02.02.0040.007113%Not Available
Cough22.02.03.0010.757576%
Cyanosis22.02.02.007; 24.03.01.007; 23.06.04.005; 02.11.04.0040.115237%
Defaecation urgency07.02.04.0010.015649%Not Available
Depressed level of consciousness17.02.04.0020.072557%
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.024897%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.007113%
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.0030.077536%Not Available
Disorientation19.13.01.002; 17.02.05.0150.039124%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.487267%
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.053350%Not Available
Dry throat22.12.03.005; 07.06.01.0050.035567%Not Available
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia07.14.03.001; 17.02.07.003--
Dysphagia07.01.06.0030.290226%
Dysphonia22.12.03.006; 19.19.03.002; 17.02.08.0040.187793%
Dysphoria19.04.02.0040.035567%Not Available
Dyspnoea02.11.05.003; 22.02.01.0041.636790%
Dysuria20.02.02.002--
Ear pain04.03.01.0030.007113%
Ear swelling04.03.01.0140.017783%Not Available
Echolalia19.11.03.004; 17.02.08.013--Not Available
Eczema23.03.04.0060.014227%
Electroencephalogram abnormal13.07.03.001--Not Available
Endocrine disorder05.09.01.001--Not Available
Eosinophilia01.02.04.0010.014227%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene